<DOC>
	<DOCNO>NCT02425111</DOCNO>
	<brief_summary>The purpose study evaluate endoscopic remission Week 26 assess ileocolonoscopy .</brief_summary>
	<brief_title>Effect Intravenous ( IV ) Vedolizumab Mucosal Healing Crohn 's Disease</brief_title>
	<detailed_description>The drug test study call vedolizumab . Vedolizumab test treat people Crohn 's disease . This study look mucosal heal people take vedolizumab . The study enroll approximately 100 patient conduct 2 Parts . Part A consist 26-week treatment period participant receive vedolizumab 300 mg intravenously ( IV ) Day 1 Weeks 2 , 6 , 14 22 . Part B consist 26-week extension treatment period participant receive vedolizumab 300 mg IV Weeks 30 , 38 , 46 . This multi-center trial conduct worldwide . The overall time participate study approximately 70 week Parts A , B 18-Week Follow-up combine . Participants make multiple visit clinic . All participant include study also 6 month safety follow-up telephone call follow his/her last dose study drug .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has diagnosis moderately severely active Crohn 's disease ( CD ) least 3 month prior enrollment , Crohn 's Disease Activity Index ( CDAI ) score 220450 Screening Period , simple endoscopic score Crohn 's Disease ( SESCD ) score ≥7 presence least one mucosal ulceration document record ileocolonoscopy Screening assessed central reader . 4 . Has CD involvement ileum and/or colon assess ileocolonoscopy . 5 . Is male female age 18 80 year , inclusive . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 18 week last dose . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 18 week last dose . 8 . Has demonstrate inadequate response , loss response , intolerance least 1 follow agent define : Immunomodulators : . Has sign symptom persistently active disease despite history least one 12week regimen oral azathioprine ( ≥1.5 mg/kg ) 6mercaptopurine ( ≥0.75 mg/kg ) , OR ii . Has history intolerance ( include limit nausea/vomiting , abdominal pain , pancreatitis , liver function test abnormality , lymphopenia , thiopurine Smethyltransferase non wild type [ wild type define thiopurine Smethyltransferase ( TPMT ) *1/*1 ] , infection ) least 1 immunomodulator . Tumor necrosis factor alpha ( TNFα ) antagonists : . Has sign symptom persistently active disease despite history least 1 induction : 1 . Infliximab : 4week regimen 5 mg/kg , 2 dos 2 week apart , OR 2 . Adalimumab : 2week regimen 160 mg Day 1 80 mg Day 15 , OR 3 . Certolizumab : 4week regimen 400 mg initially Weeks 0 , 2 , 4 OR ii . Has recurrence symptom maintenance dose follow prior clinical benefit ( discontinuation despite clinical benefit qualify ) , OR iii . Has history intolerance infliximab , adalimumab , certolizumab , include limited , infusionrelated reaction , demyelination , congestive heart failure , infection . Corticosteroids . Signs symptom persistently active disease despite history least one 4week induction regimen include dose equivalent prednisone 30 mg daily orally 2 week intravenous ( ly ) ( IV ) 1 week , OR ii . Signs symptom persistently active disease despite treatment budesonide 9 mg daily 6 mg daily maintenance , OR iii . At least one fail attempt taper corticosteroid dose equivalent prednisone 10 mg daily orally , OR iv . History intolerance corticosteroid ( include , limited , Cushing 's syndrome , osteopenia/osteoporosis , hyperglycemia , insomnia , infection ) . 9 . May receive stable therapeutic dose conventional therapy CD ( exclude biologic agent 60 day enrollment ) . 10 . Has family history colorectal cancer , personal history increase colorectal cancer risk , age &gt; 50 year , know risk factor must uptodate colorectal cancer surveillance ( may perform Screening ) . 1 . Has receive diagnosis ulcerative colitis indeterminate colitis . 2 . Has clinical evidence abdominal abscess . 3 . Has history &gt; 3 small bowel resection diagnosis short bowel syndrome . 4 . Has extensive colonic resection , ie , subtotal total colectomy &lt; 15 cm colon remain . 5 . Has ileostomy , colostomy , know fix symptomatic stenosis intestine . 6 . Has history evidence adenomatous colonic polyp remove . 7 . Has history evidence colonic mucosal dysplasia . 8 . Has intolerance contraindication undergo ileocolonoscopy . 9 . Has active latent tuberculosis , regardless treatment history , evidence following : . History tuberculosis ( TB ) . b . A diagnostic TB test perform screen positive , define : . A positive QuantiFERON® test 2 successive indeterminate QuantiFERON test OR ii . A tuberculin skin test reaction ≥10 mm ( ≥5 mm patient receive equivalent &gt; 15 mg/day prednisone ) . 10 . Has chronic hepatitis B ( HBV ) hepatitis C ( HCV ) infection . 11 . Has identify congenital acquire immunodeficiency ( eg , common variable immunodeficiency , human immunodeficiency virus [ HIV ] infection , organ transplantation ) . 12 . Has evidence active C. difficile infection treatment C. difficile infection intestinal pathogen Screening . 13 . Has evidence active infection Screening . 14 . Currently require planned surgical intervention CD study . 15 . Has receive investigational compound within 60 day enrollment . 16 . Has receive biologics within 60 day enrollment . 17 . Has receive live vaccination within 30 day prior enrollment . 18 . Has condition , opinion investigator , may interfere participant 's ability comply study procedure . 19 . Has unstable uncontrolled cardiovascular , pulmonary , hepatic , renal , gastrointestinal ( GI ) , genitourinary , hematological , coagulation , immunological , endocrine/metabolic , medical disorder , opinion investigator , would confound study result compromise participant safety . 20 . Has history hypersensitivity allergy vedolizumab component . 21 . Has prior exposure vedolizumab , natalizumab , efalizumab , rituximab . 22 . Had surgical procedure require general anesthesia within 30 day prior screen plan undergo major surgery study period . 23 . Has history malignancy , except follow : adequatelytreated nonmetastatic basal cell skin cancer ; squamous cell skin cancer adequately treat recur least 1 year prior Screening ; history cervical carcinoma situ adequately treat recur least 3 year prior screen . Participants remote history malignancy ( eg , &gt; 10 year since completion curative therapy without recurrence ) consider base nature malignancy therapy receive must discuss sponsor casebycase basis prior enrollment . 24 . Has history major neurological disorder , include stroke , multiple sclerosis , brain tumor , neurodegenerative disease . 25 . Has positive progressive multifocal leukoencephalopathy ( PML ) subjective symptom checklist Screening prior administration study drug . 26 . Has follow laboratory abnormality Screening Period : i. Hemoglobin level &lt; 8 g/dL . ii . White blood cell ( WBC ) count &lt; 3 x 10^9/L . iii . Lymphocyte count &lt; 0.5 x 10^9/L . iv . Platelet count &lt; 100 x 10^9/L &gt; 1200 x 10^9/L . v. Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal ( ULN ) . vi . Alkaline phosphatase &gt; 3 x ULN . vii . Serum creatinine &gt; 2 x ULN . 27 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior enrollment . 28 . Has active psychiatric problem , investigator 's opinion , may interfere compliance study procedure . 29 . Is unable attend study visit comply study procedure . 30 . If female , participant pregnant lactate intend become pregnant , , within 18 week participate study ; intend donate ova time period . 31 . If male , participant intend donate sperm course study 18 week thereafter . 32 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 33 . Participants sit participate magnetic resonance enterography ( MREn ) substudy may participate intolerance contraindication procedure follow exclusion apply : 1 . Has certain implant medical device , pacemaker implantable cardioverter defibrillator ( ICDs ) , ferromagnetic metallic foreign body , shrapnel certain tattoo . 2 . Has allergy gadoliniumbased magnetic resonance ( MR ) IV contrast agent . 3 . Has know claustrophobia . 4 . Has estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m^2 Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>